medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

The role of age distribution, time lag between reporting and death and healthcare system capacity on case fatality estimates of COVID-19

Patrizio Vanella[1,2], Christian Wiessner[2,3], Anja Holz[3,4], Gérard Krause[1,4,5], Annika Möhl[3,4], Sarah Wiegel[3,4], Berit Lange[1,5,6], Heiko Becher[3,6]

[1] Helmholtz Centre for Infection Research (HZI), Brunswick, Lower Saxony, Germany
[2] Shared first author
[3] University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
[4] In alphabetical order
[5] German Center for Infection Research (DZIF), Brunswick, Lower Saxony, Germany
[6] Shared last author

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abstract

European countries report large differences in coronavirus disease (COVID-19) case fatality risk (CFR). CFR estimates depend on demographic characteristics of the cases, time lags between reporting of infections and deaths and infrastructural characteristics, such as healthcare and surveillance capacities. We discuss the impact of these factors on the CFR estimates for Germany, Italy, France, and Spain for the COVID-19 pandemic from early March to mid-April, 2020. We found that, first, a large proportion of the difference in CFRs can be attributed to different age structures of the cases. Second, lags of 5-10 days between day of case report and death should be used, since these provide the most constant estimates. Third, for France, Italy, and Spain, intensive care beds occupied by COVID-19 patients were positively associated with fatality risks of hospitalized cases. Our results highlight that cross-country comparisons of crude CFR estimates can be misleading and should be avoided.

Introduction

Different case fatalities of COVID-19 have been reported in affected countries. Until April 16th, 2020, almost 2.2 million confirmed cases and close to 150,000 associated deaths have been identified globally (1). The crude case fatality risk (CFR) estimate, namely the cumulative number of deaths divided by the cumulative number of cases, is known to be biased (2). The main sources of bias are given in Table 1. A distinction must be made between factors that influence the actual lethality (as denoted by *), such as healthcare capacity and those that bias the estimates of the CFR, such as an underassessment of cases.

Table 1. Sources of bias of case fatality risk estimates

Factor	Description	Impact on CFR estimate	Literature
Population	Age, comorbidi-	Higher CFR given an older population with	(3-12)

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

structure*	ties and underlying risk factors	a higher load of comorbidities	
Surveillance and testing	Surveillance system and different testing capacities	Overestimation of CFR given a poor surveillance system and poor testing capacity, as fewer currently infected persons in relation to deaths are counted	(2, 13-21)
	Methods and capacities to record deaths	Underestimation of CFR given low capacities and poor quality methods to record deaths due to the disease resulting in a smaller numerator of deaths / current reported infected;	(22)
		Overestimation of CFR, if all deaths are counted regardless of whether the patient died of the target disease or another cause given the same number of infected/diseased	(22)
Time lag	Deaths occur time-delayed after infection	Underestimation of CFR given a time lag of several days between case registration and death resulting in a smaller nominator of current deaths / current infected	(12, 23)
Healthcare system*	Healthcare system capacity measured as number of intensive care beds per 100.000 inhabitants	Higher CFR given a low healthcare capacity and an additional excessive demand for intensive care beds during the pandemic resulting in more deaths and therefore a higher numerator of deaths / current infected	(4, 19, 24-28)

Different demographic characteristics of infected cases regarding age, comorbidities, or underlying risk factors**,** as well as different underlying population structures of the respective countries, might explain different CFRs. There is increasing evidence that old-age and comorbidities – such as hypertension, diabetes, cardiovascular disease, or chronic lung disease – are major risk factors for severe COVID-19 infection outcomes (7, 29, 30). The higher

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

susceptibility to disease as well as the higher prevalence of comorbidities in the elderly has an impact on the morbidity as well as mortality of this subpopulation resulting in higher CFRs in countries with an older population compared to countries with a younger age structure, which is apparent in the COVID-19 pandemic (3-5, 7-11).

Different surveillance systems and different testing capacities across countries lead to huge variations in the number of tests performed (13, 14, 18, 19, 31). Underassessment of reported infections therefore differs among countries (15-17). Furthermore, surveillance and testing capacities influence the probability of detecting infections early and thus to enact countermeasures. Capacities and methods to record deaths as having been caused by COVID-19 also differ between countries (22). While in some countries, post-mortem screening of all deaths has been installed, other countries are only performing this when there is clinical suspicion (32).

There exists a time lag between reporting of an infection and eventual death of said individual. The distribution of the time lag may differ between countries. This delay is not reflected in crude CFR estimates (23). A more robust estimate would be given by dividing cumulative deaths by cumulative recoveries. This, however, is not a reliable estimate as well due to a low number of recoveries during the early stages of the pandemic, when a high relative increase of infection numbers and an incomplete reporting of recoveries are witnessed (33). Therefore, some authors propose to investigate the cumulative deaths in relation to lags of various days of the cumulative infection numbers (23, 33). However, as a result of the high transmission rates of the virus in the early stages of the epidemic, the estimates depend strongly on the appropriate lag, and both under- and overestimation of the true CFR can occur (34). Gianicolo et al. (12) calculate age-standardized CFRs with a time lag of 7 days ranging from 0.8% in South Korea to 2.4% in Italy. In contrast, they report crude CFRs of 2.2% for South Korea and 12.6% for Italy.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Furthermore, CFRs are influenced by the healthcare system capacity of the affected countries. Previous studies have shown, that healthcare capacities differ substantially among countries, and even among regions within countries (4, 19, 24-28). A healthcare system overwhelmed by the pandemic may result in higher CFRs.

All factors mentioned above may explain differences in CFRs in affected countries to a certain degree at different time points during the COVID-19 pandemic. It is unclear, how much of the difference in during-epidemic CFR estimates is explained by each of these factors. The aims of this paper are as follows: (i) to quantify the difference in during-epidemic case fatality due to COVID-19 between the countries Germany, Italy, France, and Spain attributed to differences in the age structures among the reported cases, (ii) to investigate the time lag between case reporting and death and its effect on CFR estimation, and (iii) to discuss the association between CFR and the healthcare system capacity. The selected countries are interesting for our study, as they are the four most populous countries in the European Union (EU), covering more than half of the total population of the EU (35). Moreover, these countries show different levels in COVID-19 CFRs and have born a large part of the COVID-19 disease burden in the last two months.

Data and Methods:

To investigate the age effect, we obtained the cumulative numbers of cases and deaths of Germany (36-42), Italy (43-50), France (51-57), and Spain (58-64) by age group for different dates as provided from the websites of the national health authorities. For comparison of crude and age-adjusted CFRs, we used the European Standard Population (65) for standardization. The effect of different time lags on CFR estimates was analyzed using data provided daily by the European Centre for Disease Prevention and Control (ECDC) (66). For our investigation of the impact of the healthcare system capacity, we take estimates for the available

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

critical care beds from the OECD (67) and of needed critical care beds for COVID-19 patients on a daily basis from the Institute for Health Metrics and Evaluation (IHME) (68-71).

We use the following notation: n_{ijk} and d_{ijk} denote the total cumulative number of cases and deaths, respectively, for age group i, country j, and up to day k. $\delta_{.jk}$ denotes the number of deaths at day k, i.e. $d_{.jk} = \sum_{\kappa=1}^{k} \delta_{j\kappa}$.

Figure 1 illustrates the development of the crude CFR estimates of the four selected countries in percent between March 4th (i.e., calendar week 10) and April 16th (i.e., calendar week 16), 2020 as obtained by $CFR_{jk} = d_{.jk}/n_{.jk}$. These crude estimates do not take into account the factors listed in Table 1.

Figure 1. Crude Case Fatality Risk Estimates due to COVID-19 between March 4th and April 16th, 2020 Sources: (66); Own computation and design

All curves increased over the study period. We observed significant differences between the curves. Our study aims to explain these differences to some extent.

The first aim was to identify the role of the cases' age structure on the overall CFRs and to derive age-specific and age-standardized CFR estimates of Germany, Italy, France, and Spain. Based on the age-specific cases n_{ijk} of the four European countries, we calculated the age-specific CFR, $CFR_{ijk} = d_{ijk}/n_{ijk}$, the total crude CFR estimate, $CFR_{jk} = d_{.jk}/n_{.jk}$ and the age-standardized CFR estimate as $\widetilde{CFR}_{jk} = \sum_i w_i \times d_{ijk}/n_{ijk}$ using the European Standard Population as a reference. To illustrate the relative effect of the different age distributions of cases in the countries considered, we calculated the ratio of the relative differences between the crude and age-adjusted CFR estimates, using Germany as the reference country, as it is the country with the lowest crude CFRs.

For the second aim, namely, to investigate the effect of different lags on the CFR estimate, the unknown distribution of the time lag Δ between reporting of a case and death was

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

considered. Verity et al. (72) estimated the average time from infection to death at about 14 days. Thus, the average time from reporting a case to death is several days shorter. The effect of Δ on the CFR estimate was evaluated by calculating $CFR_{k,\Delta} = d_{.jk}/n_{.jk-\Delta}$ for the pandemic for $k = 0$ over the study period with $\Delta = 0, \ldots, 10$. We graphically determined the values $\tilde{\Delta}$, which appear to converge to the final CFR of the epidemic over time, in particular during the peak of the pandemic. We then present the figures for Germany, Italy, Spain and France.

The third aim was to investigate the association between the daily hospitalization fatality and the healthcare capacity of a specific country. As a suitable measure for the daily hospitalization fatality**,** we suggest the number of COVID-19 related fatalities of a particular day divided by the number of hospital admissions due to COVID-19 of the last 14 days:

$$Daily\ hospitalization\ fatality_{jk} = \frac{\delta_{jk}}{\sum_{\kappa=k-14}^{k} h_{j\kappa}}$$

A period of the preceding two weeks was used to (a) remove the weekly periodicity and (b) because of a reported median hospitalization length of stay of 8 days (73, 74). As a measure of the utilization of healthcare capacities, the number of intensive care beds needed for COVID-19 patients was chosen. The analysis only included days where at least 5% of the total number of intensive care beds of a country were needed for COVID-19 patients, because with lower numbers no overload of the intensive care bed capacity could be expected (67).

We then related the daily hospitalization fatality to the number of intensive care beds needed (68-71). The total number of intensive care beds available is included in Figure 4 as a threshold, above which demand exceeded capacity.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Results:

Aim 1. During-epidemic crude and age-standardized CFR estimates, alongside CFR ratios of Germany, Italy, France and Spain

Table 2[1] provides weekly estimates of crude and age-standardized CFRs, estimated as explained in the section Data and Methods. Moreover, the standardized CFRs are normalized to Germany's age-standardized CFR as the baseline, to investigate how much higher the CFRs were in Italy, France and Spain compared to Germany after accounting for the age structure of the cases.

Table 2. Crude and standardized CFRs in % for Germany, Italy, France and Spain by calendar week 2020

Week	**Variable**	**Country**			
		Germany	**Italy**	**France**	**Spain**
16	CFR (crude)	2.55	12.57	16.08	10.48
	ratio[2]	1.0 (reference)	4.93	6.31	4.11
	CFR (age-standardized)	1.8	5.25	5.48	3.77
	ratio[3]	1.0 (reference)	2.92	3.05	2.10
15	CFR (crude)	1.8	12.24	10.89	9.92
	ratio[1]	1.0 (reference)	6.80	6.05	5.51
	CFR (age-standardized)	1.41	5.16	4.84	2.65
	ratio[2]	1.0 (reference)	3.66	3.43	1.88
14	CFR (crude)	1.09	11.80	9.83	9.19
	ratio[1]	1.0 (reference)	10.83	9.02	8.43
	CFR (age-standardized)	1.05	4.90	3.70	3.01
	ratio[2]	1.0 (reference)	4.66	3.52	2.87
13	CFR (crude)	0.47	9.22	4.93	7.71
	ratio[1]	1.0 (reference)	19.62	10.49	16.40
	CFR (age-standardized)	0.56	3.78	2.02	1.73

[1] More detailed data, separated by age group, can be found in Tables 3-6 in the Appendix.

[2] For country in column j: $\frac{Crude\ CFR\ of\ country\ j}{Crude\ CFR\ of\ Germany}$.

[3] For country in column j: $\frac{Age-standardized\ CFR\ of\ country\ j}{Age-standardized\ CFR\ of\ Germany}$.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

	ratio[2]	1.0 (reference)	6.75	3.60	3.09
12	CFR (crude)	0.15	8.53	2.52	0.05
	ratio[1]	1.0 (reference)	56.87	16.80	0.33
	CFR (age-standardized)	0.23	3.42	1.35	0.00
	ratio[2]	1.0 (reference)	14.87	5.89	-
11	CFR (crude)	0.19	5.36	2.21	0.03
	ratio[1]	1.0 (reference)	28.21	11.63	0.16
	CFR (age-standardized)	0.68	1.93	1.60	0.00
	ratio[2]	1.0 (reference)	2.84	2.35	-

Sources: (36-66); Own computation and design

Trends in all countries examined are similar, with higher age-specific risks in older age groups. At the end of our study period, age-specific case fatalities for persons above age 79, the oldest identifiable age group, were 16% in Germany, 20% in Spain, more than one quarter in France and about 30% in Italy, whereas age-specific fatality for those under 60 years of age was consistently below 5% in all countries (see Tables 3-6).

Figure 2. Crude and age-standardized CFR estimates Sources: (36-65); own computation and design

Until mid-April, the proportion of cases exceeding 60 years of age (among those with known age) was above 50% in Italy, Spain and France, compared to below 30% in Germany, yet the trend in Germany was positive. For Germany, the age-standardized CFR estimates show a smaller increase than the crude CFRs over time, caused by the changing age distribution of the cases towards a higher proportion of older cases.

Aim 2. Assess different potential time lags for the CFR estimates

Figure 3 shows the crude estimates for the CFR during the study period using lags of 0 to 10 days.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 3. Crude CFR estimates for Germany, Italy, France and Spain from February 29th, 2020 until April 16th, 2020, with different time lags Sources: (66); Own computation and design

For all countries, the estimates with different lags converged, since the number of newly detected cases was generally decreasing towards the end of our observation period. In Germany and France, a longer time lag, such as 8 to 10 days, yielded estimates over time, which were close to the current estimates. A lag of about 4 days yields fairly constant estimates over time in Italy and Spain. The most recent estimates for April 16th, 2020 yielded crude CFR estimates ranging between lags of 0 to 10 days of 0.03-0.04, 0.13-0.17, 0.10-0.14, and 0.17-0.24 for Germany, Italy, France and Spain, respectively. Ignoring the time lag yielded to an underestimation of the CFR at peak times of the pandemic. This underestimation was stronger in Germany, and therefore the comparison of the estimates with those from the other three countries showed larger differences at this period compared to mid-April. For example, the estimated crude CFRs in Germany and Spain on March 21st were 0.24% and 5%, respectively. On April 16th, these were 2.7% and 10.4%. The corresponding CFR ratios decreased from 20.8 to 3.9.

Aim 3. Describe the association between case fatality and the intensive care bed capacity

We define the daily hospitalization fatality as the deaths on a particular day relative to the total number of hospitalized cases admitted during the previous two weeks. In Germany, e.g., 315 persons died on April 16th, 2020, and 11,373 cases were hospitalized in the previous two weeks, which leads to a daily hospitalization fatality of 2.77%. Figure 4 illustrates the daily fatality of hospitalized cases in association with the needed intensive care bed capacities. The

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

total available intensive care bed capacities, taken from OECD (67), are indicated by vertical lines.

Figure 4. Daily hospitalization fatality relative to intensive care beds needed for COVID-19 patients Sources: (66-71); Own computation and design

The countries in our analysis were at different stages in terms of the capacity utilization of their intensive care beds. At the end of our analysis, France had the highest number of COVID-19 cases requiring a treatment in an intensive care unit (5,615), followed by Spain (5,318), Italy (4,750), and Germany (2,030). We observe a positive correlation of the daily hospitalization fatalities with the intensive care beds needed for COVID-19 patients on a particular day in France, Italy, and Spain. For Germany, the number of intensive care beds occupied by COVID-19 patients has so far consistently been below the available capacity.

Discussion:

There are large differences in the reported CFRs between countries. We discussed factors that may explain shares of these differences. We present evidence that a large proportion of the differences of CFRs between the four countries studied here can be attributed to different age distributions of cases. Moreover, we have shown, that crude CFR estimates are strongly biased at peak phases of the pandemic due to lags between case reporting and death. This bias becomes smaller when daily case numbers decrease. It is unclear, how different CFRs among the European countries are indeed an indicator of differences in healthcare capacity. In the countries considered here, we could show an association between the number of intensive care beds needed for COVID-19 patients and daily hospitalization fatality.

Our analysis only considered the impact of the three factors demographics, delay in deaths after infection, and healthcare system capacity on CFR estimates of COVID-19. There

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

are certainly other factors, which play into country-specific differences as well. Among those may be environmental factors, such as air pollution or climatic circumstances (75). Moreover, there are differences in the overall mortality among countries (76), which should be taken into account for a holistic international comparison of COVID-19 and general cause-specific mortality.

Generally, differences in CFR estimates which remain after adjusting for population structure, time lags, and health care capacity are most likely an indicator of different extents of underreporting of COVID-19 cases across countries caused by limited surveillance capacities of the countries' health systems. Underassessment of COVID-19 cases can be assumed for most countries, with varying extent (77). For persons not belonging to population groups at high risk of severe COVID-19 clinical courses, the disease in some cases appears with only minor symptoms or no symptoms at all (78). Thus, many mild cases may not appear in the statistics and therefore bias the data towards the more severe cases (2, 21), overestimating the overall fatality risk. For example, the number of undocumented cases was estimated to be 86% of all infections in China at the end of January (16) and 72% of all infections in Italy using international travel data at the end of February (79). One example of a situation with presumably very low underassessment is a study conducted on the cruise ship Diamond Princess (80). All passengers were tested, and 696 Passengers were tested positive. According to recent data, eight individuals have died due to COVID-19, yielding a crude fatality risk of 1.15%, resulting from the passengers' high mean age. The age-standardized CFR in this population is 0.65%. Although the study population was small yielding an imprecise estimate, it may roughly indicate the proportion of unobserved cases among other populations, assuming the fatality in the ship's population was comparable to that of the countries considered in this paper.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Besides underassessment due to underdetection of asymptomatic or mildly symptomatic cases, the diagnostic accuracy of tests plays a role. The WHO recommends RT-PCR to detect the virus in pharyngeal swabs (20). Differences in viral load at various time points after infection and at different locations (18) make a reliable detection of the virus difficult. A study of Fang et al. showed 71% sensitivity of RT-PCR compared to 98% of chest-CT (14). Thus, low sensitivity would also result in underreporting of COVID-19 and therefore in an overestimation of case fatality.

The extent of underassessment of cases can also be assumed to vary during country infection dynamics. Underreporting may appear more severely in the early and later stages of the epidemic (2), as the disease in the earlier stages can be mistaken as another respiratory syndrome due to similar symptoms (81). In the peak stages of the epidemic, there might be an overload of the reporting system due to the high number of cases and limited capacities of laboratories (20), which might lead to a general underestimation of cases and therefore an overestimation of the fatality risks.

As an important limitation of our work, we found that public data on the age structure of infected and deceased were missing in public reports on COVID-19 in many European countries. Even for the included countries, this data was partly only available at specific time points, for roughly aggregated age groups, or only for a selection of all reported cases or deaths. For other countries, age-specific data are not openly available at all. Another limitation of this work is that we were not able to gain information on the distribution of comorbidities relevant to COVID-19 over age groups of infected and deceased in the European countries assessed, thus limiting our understanding of differences in CFR estimates due to differences in comorbidities. For the analysis of the association between fatality and the healthcare load measured by intensive care beds needed, we could not incorporate the age structure or severity of hospitalized cases into our computations, because these data were not available.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Additionally, we did not have access to daily numbers of intensive care beds available for COVID-19 patients, which is why we chose to retain the absolute values of intensive care beds needed.

For publicly available data to have public health consequences, better reporting of data on healthcare capacities on a daily or at least weekly scale is needed in Europe. More detailed data on the demographics of the cases and deaths would help our understanding of the demographic impact on the CFRs. There are very few countries providing this information in a sufficiently detailed form (such as Spain and Italy do) and many countries do not offer age-stratified data at all or do not provide their data by sex. This biases our understanding of the severity of the disease, as genders show significant differences in susceptibility to severe disease and general mortality (76, 82). Even health authorities offering data on the age structure of the cases and deaths do not separate the age groups in the same manner (see, e.g., Tables 3-6). Important databases give only the crude case and death numbers, without further disaggregation, which might lead to misinterpretation of the true mortality differences among the countries. Moreover, this data should be merged with comorbidity-specific information to take this into account simultaneously in a sophisticated statistical analysis. In summary, the age structure of cases, population differences regarding underlying comorbidities and risk factors, appropriate consideration of the time lag between reported infections and death, the capacity of the health system and, most importantly, potential underassessment of cases or deaths due to limited surveillance capacities are important to understand the differences between reported country-specific CFR estimates. Our study has also shown that further improvement towards a better coordinated and unified public health data reporting system in Europe and worldwide is highly warranted to master any other pandemic that may emerge in the future.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Acknowledgments

PV, BL, and GK received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 101003480. The research of HB, AH, AM and SW was supported by a grant from the German Federal Ministry of Education and Research (Grant Number 01ER1306).

Corresponding Author:

Patrizio Vanella

Helmholtz Centre for Infection Research

Department of Epidemiology

DE-38124 Brunswick

patrizio.vanella@helmholtz-hzi.de

phone: +49 531 61 81 31 21

References

1. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 89. 2020 Apr 18 [cited 2020 Apr 18]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
2. Lipsitch M, Donnelly CA, Fraser C, Blake IM, Cori A, Dorigatti I, et al. Potential Biases in Estimating Absolute and Relative Case-Fatality Risks during Outbreaks. PLoS Negl Trop Dis. 2015;9(7):e0003846.
3. Cai H. Sex difference and smoking predisposition in patients with COVID-19. The Lancet Respiratory Medicine. 2020;8(4):E20.
4. European Centre for Disease Prevention and Control. Novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU / EEA and the UK - sixth update. 2020 Mar 12 [cited 2020 Apr 18]. https://www.ecdc.europa.eu/sites/default/files/documents/RRA-sixth-update-Outbreak-of-novel-coronavirus-disease-2019-COVID-19.pdf.
5. Shim E, Tariq A, Choi W, Lee Y, Chowell G. Transmission potential and severity of COVID-19 in South Korea. Int J Infect Dis. 2020;93:339-44.
6. Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis. J Med Virol. 2020;92(6):612-7.
7. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med. 2020;26:506-10.
8. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19). Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

9. Xie J, Tong Z, Guan X, Du B, Qiu H, Slutsky AS. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med. 2020;46(5):837-40.
10. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-5.
11. Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Feb 19;doi: 10.1111/all.14238.
12. Gianicolo E, Riccetti N, Blettner M, Karch A. Epidemiological Measures in the Context of the COVID-19 Pandemic. Deutsches Ärzteblatt International. 2020;117:336-42.
13. European Centre for Disease Prevention and Control. Sentinel surveillance. 2020 Mar 24 [cited 2020 Mar 24]; Available from: https://www.ecdc.europa.eu/en/seasonal-influenza/surveillance-and-disease-data/facts-sentinel-surveillance.
14. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology. 2020:200432.
15. Lau H, Khosrawipour V, Kocbach P, Mikolajczyk A, Ichii H, Schubert J, et al. Internationally lost COVID-19 cases. J Microbiol Immunol Infect. 2020;S1684-1182(20)30073-6.
16. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (COVID-19). Science. 2020;368(6490):489-93.
17. Niehus R, De Salazar PM, Taylor A, Lipsitch M. Quantifying bias of COVID-19 prevalence and severity estimates in Wuhan, China that depend on reported cases in international travelers. medRxiv. 2020;doi: 2020.02.13.20022707.
18. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. The Lancet Infect Dis. 2020;20(4):411-2.
19. Rajgor DD, Lee MH, Archuleta S, Bagdasarian N, Quek SC. The many estimates of the COVID-19 case fatality rate. The Lancet Infect Dis. 2020;doi: 10.1016/S1473-3099(20)30244-9.
20. World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. Interim guidance. 2020 Mar 19 [cited 2020 Apr 18]; Available from: https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117.
21. Reich NG, Lessler J, Cummings DAT, Brookmeyer R. Estimating Absolute and Relative Case Fatality Ratios from Infectious Disease Surveillance Data. Biometrics. 2012;68(2):598-606.
22. Gordis L. Epidemiology. 5th ed. Philadelphia: Elsevier Saunders; 2014.
23. Wilson N, Kvalsvig A, Barnard LT, Baker MG. Case-Fatality Risk Estimates for COVID-19 Calculated by Using a Lag Time for Fatality. Emerg Infect Dis. 2020 Mar 13;26(6).
24. Rhodes A, Ferdinande P, Flaatten H, Guidet B, Metnitz PG, Moreno RP. The variability of critical care bed numbers in Europe. Intensive Care Med. 2012;38(10):1647-53.
25. Eriksson CO, Stoner RC, Eden KB, Newgard CD, Guise J-M. The Association Between Hospital Capacity Strain and Inpatient Outcomes in Highly Developed Countries: A Systematic Review. J Gen Intern Med. 2017;32(6):686-96.
26. Eurostat. Eurostat Statistics Explained: Healthcare resources statistics - beds. 2019 Nov 29 [cited 2020 Apr 18]; Available from: https://ec.europa.eu/eurostat/statistics-explained/index.php/Healthcare_resource_statistics_-_beds.
27. Ji Y, Ma Z, Peppelenbosch MP, Pan Q. Potential association between COVID-19 mortality and health-care resource availability. The Lancet Glob Health. 2020;8(4):e480.
28. Legido-Quigley H, Asgari N, Teo YY, Leung GM, Oshitani H, Fukuda K, et al. Are high-performing health systems resilient against the COVID-19 epidemic? The Lancet. 2020;395(10227):848-50.
29. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.
30. Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death - A long list is emerging from largely unadjusted analyses, with age near the top. BMJ. 2020;368:m1198.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

31. World Health Organization. Assessing National Capacity for the Prevention and Control and Noncommunicable Diseases: Report of the 2019 Global Survey. Geneva: World Health Organization; 2020.
32. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020; doi: 10.1001/jama.2020.4683.
33. Lipsitch M. Correspondence to: Estimating case fatality rates of COVID-19. Lancet Infect Dis. 2020; doi: 10.1016/S1473-3099(20)30245-0.
34. Spychalski P, Blazynska-Spychalska A, Kobiela J. Correspondence to: Estimating case fatality rates of COVID-19. Lancet Infect Dis. 2020; doi: 10.1016/S1473-3099(20)30246-2.
35. Eurostat. Population on 1 January by age and sex. 2020 Apr 18 [cited 2020 Apr 18]; Available from: https://ec.europa.eu/eurostat/data/database.
36. Robert Koch Institut. Täglicher Lagebericht des RKI zur Coronavirus-Krankheit 2019 (COVID-19). 04.03.2020 - Aktualisierter Stand für Deutschland. 2020 Mar 04 [cited 2020 Mar 20]; Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Archiv.html.
37. Robert Koch Institut. Täglicher Lagebericht des RKI zur Coronavirus-Krankheit 2019 (COVID-19). 11.03.2020 - Aktualisierter Stand für Deutschland. 2020 Mar 11 [cited 2020 Mar 20]; Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Archiv.html.
38. Robert Koch Institut. Täglicher Lagebericht des RKI zur Coronavirus-Krankheit 2019 (COVID-19). 18.03.2020 - Aktualisierter Stand für Deutschland. 2020 Mar 18 [cited 2020 Mar 20]; Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Archiv.html.
39. Robert Koch Institut. Täglicher Lagebericht des RKI zur Coronavirus-Krankheit 2019 (COVID-19). 25.03.2020 - Aktualisierter Stand für Deutschland. 2020 Mar 25 [cited 2020 Mar 31]; Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Archiv.html.
40. Robert Koch Institut. Täglicher Lagebericht des RKI zur Coronavirus-Krankheit 2019 (COVID-19). 01.04.2020 - Aktualisierter Stand für Deutschland. 2020 Apr 01 [cited 2020 Apr 01]; Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Archiv.html.
41. Robert Koch Institut. Täglicher Lagebericht des RKI zur Coronavirus-Krankheit 2019 (COVID-19). 08.04.2020 - Aktualisierter Stand für Deutschland. 2020 Apr 08 [cited 2020 Apr 08]; Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Archiv.html.
42. Robert Koch Institut. Täglicher Lagebericht des RKI zur Coronavirus-Krankheit 2019 (COVID-19). 15.04.2020 - Aktualisierter Stand für Deutschland. 2020 Apr 15 [cited 2020 Apr 17]; Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Archiv.html.
43. Istituto Superiore di Sanità. Studio ISS Su 105 deceduti con Covid-2019, età media 81 anni e patologie preesistenti in due terzi dei casi. Comunicati stampa 15/2020. 2020 Mar 05 [cited 2020 Apr 01]; Available from: https://www.iss.it/en/comunicati-stampa/-/asset_publisher/fjTKmjJgSgdK/content/id/5286166?_com_liferay_asset_publisher_web_portlet_AssetPublisherPortlet_INSTANCE_fjTKmjJgSgdK_redirect=https%3A%2F%2Fwww.iss.it%2Fen%2Fcomunicati-stampa%3Fp_p_id%3Dcom_liferay_asset_publisher_web_portlet_AssetPublisherPortlet_INSTANCE_fjTKmjJgSgdK%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26_com_liferay_asset_publisher_web_portlet_AssetPublisherPortlet_INSTANCE_fjTKmjJgSgdK_cur%3D0%26p_r_p_resetCur%3Dfalse%26_com_liferay_asset_publisher_web_portlet_AssetPublisherPortlet_INSTANCE_fjTKmjJgSgdK_assetEntryId%3D5286166.
44. Istituto Superiore di Sanità. Letalità in Italia minore di quella della Cina per tutte le fasce di età. Comunicati stampa 16/2020. 2020 Mar 06 [cited 2020 Apr 01]; Available from: https://www.iss.it/en/comunicati-stampa/-

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

/asset_publisher/fjTKmjJgSgdK/content/id/5288119?_com_liferay_asset_publisher_web_portlet_AssetPublisherPortlet_INSTANCE_fjTKmjJgSgdK_redirect=https%3A%2F%2Fwww.iss.it%2Fen%2Fcomunicati-stampa%3Fp_p_id%3Dcom_liferay_asset_publisher_web_portlet_AssetPublisherPortlet_INSTANCE_fjTKmjJgSgdK%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26_com_liferay_asset_publisher_web_portlet_AssetPublisherPortlet_INSTANCE_fjTKmjJgSgdK_cur%3D0%26p_r_p_resetCur%3Dfalse%26_com_liferay_asset_publisher_web_portlet_AssetPublisherPortlet_INSTANCE_fjTKmjJgSgdK_assetEntryId%3D5288119.

45. Istituto Superiore di Sanità. Sorveglianza Integrata COVID-19 in Italia. AGGIORNAMENTO 11 marzo 2020. 2020 Mar 11 [cited 2020 Mar 12]; Available from: https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati.

46. Istituto Superiore di Sanità. Epidemia COVID-19. Aggiornamento nazionale. 19 marzo 2020 - ore 16:00. 2020 Mar 19 [cited 2020 Mar 23]; Available from: https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati.

47. Istituto Superiore di Sanità. Epidemia COVID-19. Aggiornamento nazionale. 26 marzo 2020 - ore 16:00. 2020 Mar 26 [cited 2020 Apr 09]; Available from: https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati.

48. Istituto Superiore di Sanità. Epidemia COVID-19. Aggiornamento nazionale. 2 aprile 2020 - ore 16:00. 2020 Apr 02 [cited 2020 Apr 09]; Available from: https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati.

49. Istituto Superiore di Sanità. Epidemia COVID-19. Aggiornamento nazionale. 9 aprile 2020 - ore 16:00. 2020 Apr 09 [cited 2020 Apr 17]; Available from: https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati.

50. Istituto Superiore di Sanità. Epidemia COVID-19. Aggiornamento nazionale. 16 aprile 2020 - ore 16:00. 2020 Apr 16 [cited 2020 Apr 17]; Available from: https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati.

51. Santé publique France. COVID-19: Point épidémiologique - Situation au 4 mars 2020 - 16h. 2020 Mar 04 [cited 2020 Mar 31; Available from: https://www.santepubliquefrance.fr/recherche/#search=COVID-19%20:%20point%20%C3%A9pid%C3%A9miologique.

52. Santé publique France. COVID-19: Point épidémiologique - Situation au 10 mars 2020 à minuit. 2020 Mar 10 [cited 2020 Mar 15]; Available from: https://www.santepubliquefrance.fr/recherche/#search=COVID-19%20:%20point%20%C3%A9pid%C3%A9miologique.

53. Santé publique France. COVID-19: Point épidémiologique - Situation au 15 mars 2020 à minuit. 2020 Mar 15 [cited 2020 Mar 20]; Available from: https://www.santepubliquefrance.fr/recherche/#search=COVID-19%20:%20point%20%C3%A9pid%C3%A9miologique.

54. Santé publique France. COVID-19: Point épidémiologique hebdomaire du 24 mars 2020. 2020 Mar 24 [cited 2020 Mar 27]; Available from: https://www.santepubliquefrance.fr/recherche/#search=COVID-19%20:%20point%20%C3%A9pid%C3%A9miologique.

55. Santé publique France. COVID-19: Point épidémiologique hebdomaire du 2 avril 2020. 2020 Apr 02 [cited 2020 Apr 03]; Available from: https://www.santepubliquefrance.fr/recherche/#search=COVID-19%20:%20point%20%C3%A9pid%C3%A9miologique.

56. Santé publique France. COVID-19: Point épidémiologique hebdomaire du 09 avril 2020. 2020 Apr 09 [cited 2020 Apr 10]; Available from: https://www.santepubliquefrance.fr/recherche/#search=COVID-19%20:%20point%20%C3%A9pid%C3%A9miologique.

57. Santé publique France. COVID-19: Point épidémiologique hebdomaire du 16 avril 2020. 2020 Apr 16 [cited 2020 Apr 17]; Available from:

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

https://www.santepubliquefrance.fr/recherche/#search=COVID-19%20:%20point%20%C3%A9pid%C3%A9miologique.
58. Instituto de Salud Carlos III. Informe sobre los casos de COVID-19 confirmados en España. Informe COVID-19 nº 6. 05 de marzo de 2020. 2020 Mar 05 [cited 2020 Apr 01]; Available from: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/InformesCOVID-19.aspx.
59. Instituto de Salud Carlos III. Informe sobre la situación de COVID-19 en España. Informe COVID-19 nº 8. 11 de marzo de 2020. 2020 Mar 11 [cited 2020 Apr 01]; Available from: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/InformesCOVID-19.aspx.
60. Instituto de Salud Carlos III. Informe sobre la situación de COVID-19 en España. Informe COVID-19 nº 11. 18 de marzo de 2020. 2020 Mar 18 [cited 2020 Apr 01]; Available from: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/InformesCOVID-19.aspx.
61. Instituto de Salud Carlos III. Informe sobre la situación de COVID-19 en España. Informe COVID-19 nº 15. 25 de marzo de 2020. 2020 Mar 25 [cited 2020 Apr 01]; Available from: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/InformesCOVID-19.aspx.
62. Instituto de Salud Carlos III. Informe sobre la situación de COVID-19 en España. Informe COVID-19 nº 19. 1 de abril de 2020. 2020 Apr 01 [cited 2020 Apr 03]; Available from: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/InformesCOVID-19.aspx.
63. Instituto de Salud Carlos III. Informe sobre la situación de COVID-19 en España. Informe COVID-19 nº 21. 6 de abril de 2020. 2020 Apr 06 [cited 2020 Apr 10]; Available from: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/InformesCOVID-19.aspx.
64. Instituto de Salud Carlos III. Informe sobre la situación de COVID-19 en España. Informe COVID-19 nº 22. 13 de abril de 2020. 2020 Apr 13 [cited 2020 Apr 17]; Available from: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/InformesCOVID-19.aspx.
65. Gesundheitsberichtserstattung des Bundes. Im Informationssystem der GBE zur Altersstandardisierung benutzte Standardbevölkerungen. Gliederungsmerkmale: Alter, Geschlecht, Standardbevölkerung. 2020 Apr 17 [cited 2020 Apr 17]; Available from: http://www.gbe-bund.de/.
66. European Centre for Disease Prevention and Control. Download today's data on the geographic distribution of COVID-19 cases worldwide. 2020 Apr 18 [cited 2020 Apr 18]; Available from: https://www.ecdc.europa.eu/en/publications-data/download-todays-data-geographic-distribution-covid-19-cases-worldwide.
67. OECD. Beyond Containment: Health systems responses to COVID-19 in the OECD. 2020 Apr 16 [cited 2020 Apr 18]; Available from: https://read.oecd-ilibrary.org/view/?ref=119_119689-ud5comtf84&Title=Beyond%20Containment:Health%20systems%20responses%20to%20COVID-19%20in%20the%20OECD.
68. Institute for Health Metrics and Evaluation. COVID-19 Projections: Germany. 2020 Apr 29 [cited 2020 Apr 29]; Available from: https://covid19.healthdata.org/germany
69. Institute for Health Metrics and Evaluation. COVID-19 Projections: Italy. 2020 Apr 29 [cited 2020 Apr 29]; Available from: https://covid19.healthdata.org/italy
70. Institute for Health Metrics and Evaluation. COVID-19 Projections: France. 2020 Apr 29 [cited 2020 Apr 29]; Available from: https://covid19.healthdata.org/france
71. Institute for Health Metrics and Evaluation. COVID-19 Projections: Spain. 2020 Apr 29 [cited 2020 Apr 29]; Available from: https://covid19.healthdata.org/spain
72. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020; doi: 10.1016/S1473-3099(20)30243-7.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

73. IHME COVID-19 health service utilization forecasting team. Forecasting the impact of the first wave of the COVID-19 pandemic on hospital demand and deaths for the USA and European Economic Area countries. medRxiv. 2020; doi: 10.1101/2020.04.21.20074732.
74. Dreher M, Kersten, A., Bickenbach, J., Balfanz, P., Hartmann, B., Cornelissen, C., ... & Brokmann, J. C. . The Characteristics of 50 Hospitalized COVID-19 Patients With and Without ARDS. Deutsches Ärzteblatt International. 2020:117(10), 271.
75. Contini D, Costabile F. Does Air Pollution Influence COVID-19 Outbreaks? Atmosphere. 2020;11(4):377.
76. Vanella P. A principal component model for forecasting age- and sex-specific survival probabilities in Western Europe. Zeitschrift für die gesamte Versicherungswissenschaft (German Journal of Risk and Insurance). 2017;106(5):539-54.
77. Zhao S, Musa SS, Lin Q, Ran J, Yang G, Wang W, et al. Estimating the Unreported Number of Novel Coronavirus (2019-nCOV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak. Journal of Clinical Medicine. 2020;9(2):388.
78. Istituto Superiore di Sanità. Sorveglianza Integrata COVID-19 in Italia. AGGIORNAMENTO 08 aprile 2020. 2020 Apr 08 [cited 2020 Apr 08]; Available from: https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati.
79. Tuite AR, Ng V, Rees E, Fisman D. Estimation of COVID-19 outbreak size in Italy. Lancet Infect Dis. 2020;20(5):537.
80. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance. 2020;25(10):2000180.
81. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 46. 2020 March 06 [cited 2020 May 14]; Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
82. Spagnolo PA, Manson JE, Joffe H. Sex and Gender Differences in Health: What the COVID-19 Pandemic Can Teach Us. Annals of Internal Medicine. 2020; doi: 10.7326/M20-1941.

Appendix

Table 3. Age-specific, crude and age-standardized CFR Estimates for Germany

Date	Age group	Confirmed cases n_{ij}	Observed deaths d_{ij}	Age-specific crude CFR (%)	European Standard Population (weights)	Age-standard-ized CFR (%)
15.04.2020	0-59	90,060	150	0.17	0.745	
	60-79	24,669	1,051	4.26	0.205	
	80+	12,625	2,048	16.22	0.050	
	Unknown	230	5	2.17		

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

	Total	**127,584**	**3,254**	**2.55**	**1.000**	**1.80**
08.04.2020	0-59	74,617	87	0.12	0.745	
	60-79	19,935	620	3.11	0.205	
	80+	8,475	1,150	13.57	0.050	
	Unknown	201	4	1.99		
	Total	**103,228**	**1,861**	**1.80**	**1.000**	**1.41**
01.04.2020	0-59	50,998	42	0.08	0.745	
	60-79	12,394	229	1.85	0.205	
	80+	3,784	459	12.13	0.050	
	Unknown	190	2	1.05		
	Total	**67,366**	**732**	**1.09**	**1.000**	**1.05**
25.03.2020	0-4	234	0	0.00	0.050	
	5-14	651	0	0.00	0.110	
	15-34	7,877	0	0.00	0.240	
	35-79	21,507	48	0.22	0.550	
	80+	1,153	101	8.76	0.050	
	Unknown	132	0	0.00	-	-
	Total	**31,554**	**149**	**0.47**	**1.000**	**0.56**
18.03.2020	0-4	67	0	0.00	0.050	
	5-14	199	0	0.00	0.110	
	15-34	2,090	0	0.00	0.240	
	35-59	4,467	0	0.00	0.345	
	60+	1,337	12	0.90	0.255	
	Unknown	38	0	0.00		
	Total	**8,198**	**12**	**0.15**	**1.000**	**0.23**

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

11.03.2020	0-4	15	0	0.00	0.050	
	5-14	28	0	0.00	0.110	
	15-34	340	0	0.00	0.240	
	35-59	551	0	0.00	0.345	
	60-79	128	2	1.56	0.205	
	80+	14	1	7.14	0.050	
	Unknown	491	0	0.00		
	Total	**1,567**	**3**	**0.19**	**1.000**	**0.68**
04.03.2020	0-4	6	0	0.00	0.050	
	5-14	3	0	0.00	0.110	
	15-34	60	0	0.00	0.240	
	35-59	66	0	0.00	0.345	
	60-79	12	0	0.00	0.205	
	80+	0	0	-	0.050	
	Unknown	115	0	0.00		
	Total	**262**	**0**	**0.00**	**1.000**	**0.00**

Sources: (36-42, 65); Own calculation and design

Table 4. Age-specific, crude and age-standardized CFR Estimates for Italy

Date	**Age group**	**Confirmed cases n_{ij}**	**Observed deaths d_{ij}**	**Age-specific crude CFR (%)**	**European Standard Population (weights)**	**Age-standard-ized CFR (%)**
16.04.2020	0-9	1,123	1	**0.09**	0.105	
	10-19	1,804	0	**0.00**	0.110	
	20-29	7,737	7	**0.09**	0.120	

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

	30-39	11,686	40	**0.34**	0.135	
	40-49	20,519	178	**0.87**	0.140	
	50-59	29,858	756	**2.53**	0.135	
	60-69	24,040	2,284	**9.50**	0.115	
	70-79	25,717	6,203	**24.12**	0.090	
	80-89	26,706	8,070	**30.22**	0.040	
	90+	9,813	2,455	**25.02**	0.010	
	Unknown	104	2	**1.92**	-	-
	Total	**159,107**	**19,996**	**12.57**	**1.000**	**5.25**
09.04.2020	0-9	938	1	**0.11**	0.105	
	10-19	1,432	0	**0.00**	0.110	
	20-29	6,360	7	**0.11**	0.120	
	30-39	9,956	36	**0.36**	0.135	
	40-49	17,745	153	**0.86**	0.140	
	50-59	26,391	638	**2.42**	0.135	
	60-69	21,734	1,957	**9.00**	0.115	
	70-79	22,934	5,366	**23.40**	0.090	
	80-89	21,636	6,711	**31.02**	0.040	
	90+	6,842	1,784	**26.07**	0.010	
	Unknown	142	1	**0.70**	-	
	Total	**136,110**	**16,654**	**12.24**	**1.000**	**5.16**
02.04.2020	0-9	693	0	**0.00**	0.105	
	10-19	931	0	**0.00**	0.110	
	20-29	4,530	6	**0.13**	0.120	
	30-39	7,466	29	**0.39**	0.135	

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

	40-49	13,701	110	**0.80**	0.140	
	50-59	20,975	479	**2.28**	0.135	
	60-69	18,089	1,448	**8.00**	0.115	
	70-79	19,238	4,196	**21.81**	0.090	
	80-89	16,252	5,029	**30.94**	0.040	
	90+	4,356	1,251	**28.72**	0.010	
	Unknown	168	2	**1.19**	-	
	Total	**106,399**	**12,550**	**11.80**	**1.000**	**4.90**
26.03.2020	0-9	428	0	**0.00**	0.105	
	10-19	512	0	**0.00**	0.110	
	20-29	2,778	0	**0.00**	0.120	
	30-39	5,033	17	**0.34**	0.135	
	40-49	9,295	67	**0.72**	0.140	
	50-59	14,508	243	**1.67**	0.135	
	60-69	13,243	761	**5.75**	0.115	
	70-79	14,198	2,403	**16.92**	0.090	
	80-89	11,001	2,702	**24.56**	0.040	
	90+	2,538	608	**23.96**	0.010	
	Unknown	246	0	**0.00**	-	
	Total	**73,780**	**6,801**	**9.22**	**1.000**	**3.78**
19.03.2020	0-9	205	0	**0.00**	0.105	
	10-19	270	0	**0.00**	0.110	
	20-29	1,374	0	**0.00**	0.120	
	30-39	2,525	9	**0.36**	0.135	
	40-49	4,396	25	**0.57**	0.140	

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

	50-59	6,834	83	**1.21**	0.135	
	60-69	6,337	312	**4.92**	0.115	
	70-79	7,121	1,090	**15.31**	0.090	
	80-89	5,352	1,243	**23.22**	0.040	
	90+	1,115	285	**25.56**	0.010	
	Unknown	202	0	**0.00**	-	
	Total	**35,731**	**3,047**	**8.53**	**1.000**	**3.42**
11.03.2020	0-49	2,484	1	**0.04**	0.610	
	50-59	2,000	10	**0.50**	0.135	
	60-69	2,080	52	**2.50**	0.115	
	70-79	2,477	213	**8.60**	0.090	
	80+	2,142	332	**15.50**	0.050	
	Unknown	355	11	**3.10**	-	
	Total	**11,538**	**619**	**5.36**	**1.000**	**1.93**
04.03.2020	0-69	1,600	8	**0.50**	0.860	
	70-79	453	24	**5.30**	0.090	
	80+	376	41	**10.90**	0.050	
	Unknown	571	32	**5.60**	-	
	Total	**3,000**	**105**	**3.50**	**1.000**	**1.45**

Sources: (43-50, 65); Own calculation and design

Table 5. Age-specific, crude and age-standardized CFR Estimates for France

Date	**Age group**	**Confirmed cases n_{ij}**	**Observed deaths d_{ij}**	**Age-specific crude CFR (%)**	**European Standard Population (weights)**	**Age-standard-ized CFR (%)**

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

	0-14	592	1	**0.17**	0.160	
	15-44	7,524	105	**1.40**	0.380	
	45-64	19,689	1,016	**5.16**	0.265	
14.04.2020	65-74	14,405	1,769	**12.28**	0.105	
	75+	28,438	7,171	**25.22**	0.090	
	Unknown	32,925	6,591	**20.02**	-	
	Total	**103,573**	**16,653**	**16.08**	**1.000**	**5.48**
	0-14	451	0	**0.00**	0.160	
	15-44	6,242	65	**1.04**	0.380	
	45-64	16,448	736	**4.47**	0.265	
07.04.2020	65-74	11,924	1,257	**10.54**	0.105	
	75+	20,826	4,975	**23.89**	0.090	
	Unknown	38,919	3,295	**8.47**	-	
	Total	**94,810**	**10,328**	**10.89**	**1.000**	**4.84**
	0-14	309	0	**0.00**	0.160	
	15-44	4,168	29	**0.70**	0.380	
	45-64	10,525	319	**3.03**	0.265	
31.03.2020	65-74	7,677	589	**7.67**	0.105	
	75+	12,524	2,539	**20.27**	0.090	
	Unknown	168	2	**1.19**	-	
	Total	**35,371**	**3,478**	**9.83**	**1.000**	**3.70**
	0-14	167	0	**0.00**	0.160	
	15-44	3,882	5	**0.13**	0.380	
24.03.2020	45-64	4,204	32	**0.76**	0.265	
	65-74	1,778	73	**4.11**	0.105	

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

	75+	2,675	397	**14.84**	0.090	
	Unknown	9,596	593	**6.18**	-	
	Total	**22,302**	**1,100**	**4.93**	**1.000**	**2.02**
15.03.2020	0-14	126	0	**0.00**	0.160	
	15-44	1,808	2	**0.11**	0.380	
	45-64	2,067	11	**0.53**	0.265	
	65-74	850	20	**2.35**	0.105	
	75+	1,236	127	**10.28**	0.090	
	Unknown	291	1	**0.34**		
	Total	**6,378**	**161**	**2.52**	**1.000**	**1.35**
10.03.2020	0-17	87	1	**1.15**	0.193	
	18-64	1,111	6	**0.54**	0.612	
	65-74	272	5	**1.84**	0.105	
	75+	349	33	**9.46**	0.090	
	Unknown	220	0	**0.00**		
	Total	**2,039**	**45**	**2.21**	**1.000**	**1.60**
04.03.2020	0-17	60	NA		0.193	
	18-64	148	NA		0.612	
	65-74	31	NA		0.105	
	75+	46	NA		0.090	
	Total	**285**	**4**	**1.40**	**1.000**	**NA**

Sources: (51-57, 65); Own calculation and design

Table 6. Age-specific, crude and age-standardized CFR Estimates for Spain

Date	**Age group**	**Confirmed cases n_{ij}**	**Observed deaths d_{ij}**	**Age-specific**	**European Standard**	**Age-standard-**

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

				crude CFR (%)	**Population (weights)**	**ized CFR (%)**
13.04.2020	0-2	168	4	**2.38**	0.030	
	2-4	64	0	**0.00**	0.010	
	5-14	303	0	**0.00**	0.110	
	15-29	6,155	14	**0.23**	0.170	
	30-39	10,764	32	**0.30**	0.135	
	40-49	16,915	97	**0.57**	0.135	
	50-59	21,057	257	**1.22**	0.130	
	60-69	18,801	795	**4.23**	0.110	
	70-79	17,912	2,386	**13.32**	0.110	
	80+	20,843	5,058	**24.27**	0.060	
	Unknown	*56,514*	9,113	**16.13**		
	Total	**169,496**	**17,756**	**10.48**	**1.000**	**3.77**
06.04.2020	0-2	98	1	**1.02**	0.030	
	2-4	47	0	**0.00**	0.010	
	5-14	230	0	**0.00**	0.110	
	15-29	4,668	6	**0.13**	0.170	
	30-39	8,348	14	**0.17**	0.135	
	40-49	12,733	46	**0.36**	0.135	
	50-59	15,754	125	**0.79**	0.130	
	60-69	14,021	378	**2.70**	0.110	
	70-79	13,446	1,201	**8.93**	0.110	
	80+	13,810	2,636	**19.09**	0.060	
	Unknown	51,346	8,934	**17.40**		

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

	Total	**134,501**	**13,341**	**9.92**	**1.000**	**2.65**
01.04.2020	0-2	98	1	**1.02**	0.030	
	2-4	39	0	**0.00**	0.010	
	5-14	176	0	**0.00**	0.110	
	15-29	3,048	6	**0.20**	0.170	
	30-39	5,335	11	**0.21**	0.135	
	40-49	7,960	41	**0.52**	0.135	
	50-59	9,449	86	**0.91**	0.130	
	60-69	8,694	272	**3.13**	0.110	
	70-79	8,648	857	**9.91**	0.110	
	80+	8,322	1,802	**21.65**	0.060	
	Unknown	50,367	6,311	**12.53**		
	Total	**102,136**	**9,387**	**9.19**	**1.000**	**3.01**
25.03.2020	0-2	60	0	**0.00**	0.030	
	2-4	20	0	**0.00**	0.010	
	5-14	112	0	**0.00**	0.110	
	15-29	1,513	3	**0.20**	0.170	
	30-39	2,349	3	**0.13**	0.135	
	40-49	3,122	8	**0.26**	0.135	
	50-59	3,416	12	**0.35**	0.130	
	60-69	3,162	58	**1.83**	0.110	
	70-79	3,339	151	**4.52**	0.110	
	80+	3,248	486	**14.96**	0.060	
	Unknown	26,962	2,926	**10.85**		
	Total	**47,303**	**3,647**	**7.71**	**1.000**	**1.73**

medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104117; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

18.03.2020	0-1	3	0	**0.00**	0.010	
	1-4	5	0	**0.00**	0.030	
	5-14	23	0	**0.00**	0.110	
	15-44	432	0	**0.00**	0.380	
	45-64	413	0	**0.00**	0.270	
	65+	381	0	**0.00**	0.200	
	Unknown	12,459	623	**0.05**		
	Total	**13,716**	**623**	**0.05**	**1.000**	**0.00**
11.03.2020	0-1	0	0	**-**	0.010	
	1-4	1	0	**0.00**	0.030	
	5-14	2	0	**0.00**	0.110	
	15-44	87	0	**0.00**	0.380	
	45-64	81	0	**0.00**	0.270	
	65+	57	0	**0.00**	0.200	
	Unknown	1,900	54	**0.03**		
	Total	**2,128**	**54**	**0.03**	**1.000**	**0.00**
04.03.2020	0-14	0	0	**-**	0.150	
	15-44	48	0	**0.00**	0.380	
	45-64	38	0	**0.00**	0.270	
	65+	21	0	**0.00**	0.200	
	Unknown	144	2	**0.01**		
	Total	**251**	**2**	**0.80**	**1.000**	**0.00**

Sources: (58-65); Own calculation and design


Germany
Italy
France
Spain
Case fatality risk (in %)
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Mar 04
Mar 11
Mar 18
Mar 25
Apr 01
Apr 08
Apr 15
Day


Germany Crude
Italy Crude
France Crude
Spain Crude
Germany Standardized
Italy Standardized
France Standardized
Spain Standardized
Case fatality risk (in %)
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Mar 04
Mar 11
Mar 18
Mar 25
Apr 01
Apr 08
Apr 15
Day


Germany
Italy
France
Spain
Case fatality risk
1.000
0.100
0.010
0.001
02/29/2020
03/14/2020
03/28/2020
04/11/2020
04/25/2020
Date
lag times
lag 0 days
lag 2 days
lag 4 days
lag 6 days
lag 8 days
lag 10 days


Country = France
Country = Germany
Country = Italy
Country = Spain
Daily hospitalization fatality (in %)
0
1
2
3
4
5
0
2000
4000
6000
8000
10000
12000
Intensive care beds needed
France
Germany
Italy
Spain